Anxiety

Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care
Clinical Guideline 22
Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care

Issue date: December 2004

This document, which contains the Institute’s full guidance on Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care, is available from the NICE website (www.nice.org.uk/CG022NICEguideline).

An abridged version of this guidance (a ‘quick reference guide’) is also available from the NICE website (www.nice.org.uk/CG022quickrefguide). Printed copies of the quick reference guide can be obtained from the NHS Response Line: telephone 0870 1555 455 and quote reference number N0763.

Information for the Public is available from the NICE website or from the NHS Response Line (quote reference number N0764 for a version in English and N0765 for a version in English and Welsh).

The distribution list for the quick reference guide to this guideline is available from www.nice.org.uk/CG022distributionlist

This guidance is written in the following context:

This guidance represents the view of the Institute, which was arrived at after careful consideration of the evidence available. Health professionals are expected to take it fully into account when exercising their clinical judgement. The guidance does not, however, override the individual responsibility of health professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

National Institute for Clinical Excellence
MidCity Place
71 High Holborn
London WC1V 6NA

www.nice.org.uk

Published by the National Institute for Clinical Excellence
December 2004

© National Institute for Clinical Excellence, December 2004. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes within the NHS. No reproduction by or for commercial organisations is allowed without the express written permission of the National Institute for Clinical Excellence.
Contents

Which NICE guideline? ........................................................................................................... 4

Key priorities for implementation ...................................................................................... 5

Key messages about anxiety disorders .............................................................................. 8

1 Guidance ............................................................................................................................ 9

2 Notes on the scope of the guidance ................................................................................. 32

3 Implementation in the NHS .............................................................................................. 33

4 Key research recommendations ...................................................................................... 34

5 Other versions of this guideline ....................................................................................... 35

6 Related NICE guidance .................................................................................................... 36

7 Review date ........................................................................................................................ 36

Appendix A: Grading scheme .............................................................................................. 37

Appendix B: The Guideline Development Group ............................................................... 38

Appendix C: The Guideline Review Panel .......................................................................... 40

Appendix D: Technical detail on the criteria for audit ..................................................... 41

Appendix E: The algorithms ................................................................................................. 50
Which NICE guideline?

What are the patient’s symptoms?

Low mood or loss of interest, usually accompanied by one or more of the following: low energy, changes in appetite, weight or sleep pattern, poor concentration, feelings of guilt or worthlessness and suicidal ideas?

Yes → Enter NICE clinical guideline on depression (www.nice.org.uk/CG023; see Section 6)

No

Apprehension, cued panic attacks, spontaneous panic attacks, irritability, poor sleeping, avoidance, poor concentration?

Yes → Enter anxiety guideline (this guideline)

No

Intermittent episodes of panic or anxiety, and taking avoiding action to prevent these feelings?

Yes → Panic disorder with or without agoraphobia (go to Step 1)

No

Episodes of anxiety triggered by external stimuli?

Yes → Agoraphobia, social phobia or simple phobia (not covered by this guideline)

No

Over-arousal, irritability, poor concentration, poor sleeping and worry about several areas most of the time

Yes → Generalised anxiety disorder (go to Step 1)
Key priorities for implementation

**General management**

- Shared decision-making between the individual and healthcare professionals should take place during the process of diagnosis and in all phases of care.

- Patients and, when appropriate, families and carers should be provided with information on the nature, course and treatment of panic disorder or generalised anxiety disorder, including information on the use and likely side-effect profile of medication.

- Patients, families and carers should be informed of self-help groups and support groups and be encouraged to participate in such programmes where appropriate.

- All patients prescribed antidepressants should be informed that, although the drugs are not associated with tolerance and craving, discontinuation/withdrawal symptoms may occur on stopping or missing doses or, occasionally, on reducing the dose of the drug. These symptoms are usually mild and self-limiting but occasionally can be severe, particularly if the drug is stopped abruptly.

**Step 1: Recognition and diagnosis of panic disorder and generalised anxiety disorder**

- The diagnostic process should elicit necessary relevant information such as personal history, any self-medication, and cultural or other individual characteristics that may be important considerations in subsequent care. (See also ‘Which NICE guideline?’, page 4.)
Step 2: Offer treatment in primary care

- There are positive advantages of services based in primary care practice (for example, lower drop-out rates) and these services are often preferred by patients.

- The treatment of choice should be available promptly.

Panic disorder

- Benzodiazepines are associated with a less good outcome in the long term and should not be prescribed for the treatment of individuals with panic disorder.

- Any of the following types of intervention should be offered and the preference of the person should be taken into account. The interventions that have evidence for the longest duration of effect, in descending order, are:
  - psychological therapy (cognitive behavioural therapy [CBT])
  - pharmacological therapy (a selective serotonin reuptake inhibitor [SSRI] licensed for panic disorder; or if an SSRI is unsuitable or there is no improvement, imipramine\textsuperscript{a} or clomipramine\textsuperscript{a} may be considered)
  - self-help (bibliotherapy – the use of written material to help people understand their psychological problems and learn ways to overcome them by changing their behaviour – based on CBT principles).

Generalised anxiety disorder

- Benzodiazepines should not usually be used beyond 2–4 weeks.

- In the longer-term care of individuals with generalised anxiety disorder, any of the following types of intervention should be offered and the preference of the person with generalised anxiety disorder

\textsuperscript{a} Imipramine and clomipramine are not licensed for panic disorder but have been shown to be effective in its management.
should be taken into account. The interventions that have evidence for the longest duration of effect, in descending order, are
- psychological therapy (CBT)
- pharmacological therapy (an SSRI)
- self-help (bibliotherapy based on CBT principles).

**Step 3: Review and offer alternative treatment**

- If one type of intervention does not work, the patient should be reassessed and consideration given to trying one of the other types of intervention.

**Step 4: Review and offer referral from primary care**

- In most instances, if there have been two interventions provided (any combination of psychological intervention, medication, or bibliotherapy) and the person still has significant symptoms, then referral to specialist mental health services should be offered.

**Step 5: Care in specialist mental health services**

- Specialist mental health services should conduct a thorough, holistic, re-assessment of the individual, their environment and social circumstances.

**Monitoring**

- Short, self-complete questionnaires (such as the panic subscale of the agoraphobic mobility inventory for individuals with panic disorder) should be used to monitor outcomes wherever possible.
Key messages about anxiety disorders

- Anxiety disorders are
  - common
  - chronic
  - the cause of considerable distress and disability
  - often unrecognised and untreated.
- If left untreated they are costly to both the individual and society.
- A range of effective interventions is available to treat anxiety disorders, including medication, psychological therapies and self-help.
- Individuals do get better and remain better.
- Involving individuals in an effective partnership with healthcare professionals, with all decision-making being shared, improves outcomes.
- Access to information, including support groups, is a valuable part of any package of care.
The following guidance is evidence based. The grading scheme used for the recommendations (A, B, C, D, NICE 2002) is described in Appendix A; a summary of the evidence on which the guidance is based is provided in the full guideline (see Section 5).

1 Guidance

This guidance makes recommendations on the management of generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults (aged 18 years and older) in primary, secondary and community care.
1.1 General management for both panic disorder and generalised anxiety disorder

People who have panic disorder or generalised anxiety disorder and their carers need comprehensive information, presented in clear and understandable language, about the nature of their condition and the treatment options available. Such information is essential for shared decision-making between patients and healthcare professionals, particularly when making choices between broadly equivalent treatments. In addition, given the emotional, social and economic costs that generalised anxiety disorder or panic disorder usually entail, patients and their families may need help in contacting support and self-help groups. Support groups can also promote understanding and collaboration between patients, their carers and healthcare professionals at all levels of primary and secondary care.

1.1.1 Shared decision-making and information provision

1.1.1.1 Shared decision-making should take place as it improves concordance and clinical outcomes. C

1.1.1.2 Shared decision-making between the individual and healthcare professionals should take place during the process of diagnosis and in all phases of care. D

1.1.1.3 Patients and, when appropriate, families and carers should be provided with information on the nature, course and treatment of panic disorder or generalised anxiety disorder, including information on the use and likely side-effect profile of medication. D

1.1.1.4 To facilitate shared decision-making, evidence-based information about treatments should be available and discussion of the possible options should take place. D
1.1.1.5 Patient preference and the experience and outcome of previous treatment(s) should be considered in determining the choice of treatment. D

1.1.1.6 Common concerns about taking medication, such as fears of addiction, should be addressed. D

1.1.1.7 In addition to being provided with high-quality information, patients, families and carers should be informed of self-help groups and support groups and be encouraged to participate in such programmes where appropriate. D

1.1.2 Language

1.1.2.1 When talking to patients and carers, healthcare professionals should use everyday, jargon-free language. If technical terms are used they should be explained to the patient. D

1.1.2.2 Where appropriate, all services should provide written material in the language of the patient, and appropriate interpreters should be sought for people whose preferred language is not English. D

1.1.2.3 Where available, consideration should be given to providing psychotherapies in the patient’s own language if this is not English. D

Stepped approaches to care

The guideline provides recommendations for care at different stages of the patient journey, represented as different steps (Sections 1.2 to 1.11):
Step 1 – recognition and diagnosis
Step 2 – treatment in primary care
Step 3 – review and consideration of alternative treatments
Step 4 – review and referral to specialist mental health services
Step 5 – care in specialist mental health services.
1.2 Step 1:  
Recognition and diagnosis of panic disorder and generalised anxiety disorder

1.2.1 Consultation skills

1.2.1.1 All healthcare professionals involved in diagnosis and management should have a demonstrably high standard of consultation skills so that a structured approach can be taken to the diagnosis and subsequent management plan for panic disorder and generalised anxiety disorder. The standards detailed in the video workbook Summative Assessment For General Practice Training: Assessment Of Consulting Skills – the MRCGP/Summative Assessment Single Route (see www.rcgp.org.uk/exam) and required of the Membership of the Royal College of General Practitioners are a good example of standards for consulting skills.

1.2.2 Diagnosis

The accurate diagnosis of panic disorder or generalised anxiety disorder is central to the effective management of these conditions. It is acknowledged that frequently there are other conditions present, such as depression, that can make the presentation and diagnosis confusing. An algorithm has been developed to aid the clinician in the diagnostic process, and to identify which guideline is most appropriate to support the clinician in the management of the individual patient (see page 4).

1.2.2.1 The diagnostic process should elicit necessary relevant information such as personal history, any self-medication, and cultural or other individual characteristics that may be important considerations in subsequent care.
1.2.2.2 There is insufficient evidence on which to recommend a well-validated, self-reporting screening instrument to use in the diagnostic process, and so consultation skills should be relied upon to elicit all necessary information.

1.2.3 Comorbidities

1.2.3.1 The clinician should be alert to the common clinical situation of comorbidity, in particular, anxiety with depression and anxiety with substance abuse.

1.2.3.2 The main problem(s) to be treated should be identified through a process of discussion with the patient. In determining the priorities of the comorbidities, the sequencing of the problems should be clarified. This can be helped by drawing up a timeline to identify when the various problems developed. By understanding when the symptoms developed, a better understanding of the relative priorities of the comorbidities can be achieved, and there is a better opportunity of developing an effective intervention that fits the needs of the individual.

1.2.3.3 When the patient has depression or anxiety with depression, the NICE guideline on management of depression should be followed (see Section 6).

1.2.4 Presentation in A&E with panic attacks

It is important to remember that a panic attack does not necessarily constitute a panic disorder and appropriate treatment of a panic attack may limit the development of panic disorder. For people who present with chest pain at A&E services, there appears to be a greater likelihood of the cause being panic disorder if coronary artery disease is not present or the patient is female or relatively young. Two other variables, atypical chest pain and self-reported anxiety, may also be associated with panic disorder presentations, but there is insufficient evidence to establish a relationship.
1.2.4.1 If a patient presents in A&E, or other settings, with a panic attack, they should: D

- be asked if they are already receiving treatment for panic disorder
- undergo the minimum investigations necessary to exclude acute physical problems
- not usually be admitted to a medical or psychiatric bed
- be referred to primary care for subsequent care, even if assessment has been undertaken in A&E
- be given appropriate written information about panic attacks and why they are being referred to primary care
- be offered appropriate written information about sources of support, including local and national voluntary and self-help groups.
Panic disorder – steps 2–5

1.3 Step 2 for people with panic disorder:
offer treatment in primary care

The recommended treatment options have an evidence base: psychological therapy, medication and self-help have all been shown to be effective. The choice of treatment will be a consequence of the assessment process and shared decision-making.

There may be instances when the most effective intervention is not available (for example, cognitive behavioural therapy [CBT]) or is not the treatment option chosen by the patient. In these cases, the healthcare professional will need to consider, after discussion with the patient, whether it is acceptable to offer one of the other recommended treatments. If the preferred treatment option is currently unavailable, the healthcare professional will also have to consider whether it is likely to become available within a useful timeframe.

1.3.1 General

1.3.1.1 Benzodiazepines are associated with a less good outcome in the long term and should not be prescribed for the treatment of individuals with panic disorder. A

1.3.1.2 Sedating antihistamines or antipsychotics should not be prescribed for the treatment of panic disorder. D

1.3.1.3 In the care of individuals with panic disorder, any of the following types of intervention should be offered and the preference of the person should be taken into account. The interventions that have evidence for the longest duration of effect, in descending order, are: A

- psychological therapy (see Section 1.3.2)
- pharmacological therapy (antidepressant medication) (see Section 1.3.3)
1.3.1.4 The treatment option of choice should be available promptly. D

1.3.1.5 There are positive advantages of services based in primary care (for example, lower rates of people who do not attend) and these services are often preferred by patients. D

1.3.2 Psychological interventions

1.3.2.1 Cognitive behavioural therapy (CBT) should be used. A

1.3.2.2 CBT should be delivered only by suitably trained and supervised people who can demonstrate that they adhere closely to empirically grounded treatment protocols. A

1.3.2.3 CBT in the optimal range of duration (7–14 hours in total) should be offered. A

1.3.2.4 For most people, CBT should take the form of weekly sessions of 1–2 hours and should be completed within a maximum of 4 months of commencement. B

1.3.2.5 Briefer CBT should be supplemented with appropriate focused information and tasks. A

1.3.2.6 Where briefer CBT is used, it should be around 7 hours and designed to integrate with structured self-help materials. D

1.3.2.7 For a few people, more intensive CBT over a very short period of time might be appropriate. C

1.3.3 Pharmacological interventions – antidepressant medication

Antidepressants should be the only pharmacological intervention used in the longer term management of panic disorder. The two classes of antidepressants that have an evidence base for effectiveness are the
selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants.

1.3.3.1 The following must be taken into account when deciding which medication to offer:

- the age of the patient
- previous treatment response
- risks
  - the likelihood of accidental overdose by the person being treated and by other family members if appropriate
  - the likelihood of deliberate self-harm, by overdose or otherwise
- tolerability
- the preference of the person being treated
- cost, where equal effectiveness is demonstrated.

1.3.3.2 All patients who are prescribed antidepressants should be informed, at the time that treatment is initiated, of potential side effects (including transient increase in anxiety at the start of treatment) and of the risk of discontinuation/withdrawal symptoms if the treatment is stopped abruptly or in some instances if a dose is missed or, occasionally, on reducing the dose of the drug.

1.3.3.3 Patients started on antidepressants should be informed about the delay in onset of effect, the time course of treatment, the need to take medication as prescribed, and possible discontinuation/withdrawal symptoms. Written information appropriate to the patient’s needs should be made available.

1.3.3.4 Unless otherwise indicated, an SSRI licensed for panic disorder should be offered.
1.3.3.5 If an SSRI is not suitable or there is no improvement after a 12-week course and if a further medication is appropriate, imipramine\textsuperscript{a} or clomipramine\textsuperscript{a} may be considered. \textsuperscript{A}

1.3.3.6 When prescribing an antidepressant, the healthcare professional should consider the following.

- Side effects on the initiation of antidepressants may be minimised by starting at a low dose and increasing the dose slowly until a satisfactory therapeutic response is achieved. \textsuperscript{D}

- In some instances, doses at the upper end of the indicated dose range may be necessary and should be offered if needed. \textsuperscript{B}

- Long-term treatment may be necessary for some people and should be offered if needed. \textsuperscript{B}

- If the patient is showing improvement on treatment with an antidepressant, the medication should be continued for at least 6 months after the optimal dose is reached, after which the dose can be tapered. \textsuperscript{D}

1.3.3.7 If there is no improvement after a 12-week course, an antidepressant from the alternative class (if another medication is appropriate) or another form of therapy (see 1.3.1.3) should be offered. \textsuperscript{D}

1.3.3.8 Patients should be advised to take their medication as prescribed. This may be particularly important with short half-life medication in order to avoid discontinuation/withdrawal symptoms. \textsuperscript{C}

1.3.3.9 Stopping antidepressants abruptly can cause discontinuation/withdrawal symptoms. To minimise the risk of

\textsuperscript{a} Imipramine and clomipramine are not licensed for panic disorder but have been shown to be effective in its management.
discontinuation/withdrawal symptoms when stopping antidepressants, the dose should be reduced gradually over an extended period of time. C

1.3.3.10 All patients prescribed antidepressants should be informed that, although the drugs are not associated with tolerance and craving, discontinuation/withdrawal symptoms may occur on stopping or missing doses or, occasionally, on reducing the dose of the drug. These symptoms are usually mild and self-limiting but occasionally can be severe, particularly if the drug is stopped abruptly. C

1.3.3.11 Healthcare professionals should inform patients that the most commonly experienced discontinuation/withdrawal symptoms are dizziness, numbness and tingling, gastrointestinal disturbances (particularly nausea and vomiting), headache, sweating, anxiety and sleep disturbances. D

1.3.3.12 Healthcare professionals should inform patients that they should seek advice from their medical practitioner if they experience significant discontinuation/withdrawal symptoms. D

1.3.3.13 If discontinuation/withdrawal symptoms are mild, the practitioner should reassure the patient and monitor symptoms. If severe symptoms are experienced after discontinuing an antidepressant, the practitioner should consider reintroducing it (or prescribing another from the same class that has a longer half-life) and gradually reducing the dose while monitoring symptoms. D

1.3.4 Self-help

1.3.4.1 Bibliotherapy based on CBT principles should be offered. A

1.3.4.2 Information about support groups, where they are available, should be offered. (Support groups may provide face-to-face meetings, telephone conference support groups [which can be
1.3.4.3 The benefits of exercise as part of good general health should be discussed with all patients as appropriate. B

1.3.4.4 Current research suggests that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence is, however, an insufficient basis on which to recommend the general introduction of this technology into the NHS. NICE 2002
1.4 **Step 3 for people with panic disorder:**

**review and offer alternative treatment if appropriate**

1.4.1.1 If, after a course of treatment, the clinician and patient agree that there has been no improvement with one type of intervention, the patient should be reassessed and consideration given to trying one of the other types of intervention. D

1.5 **Step 4 for people with panic disorder:**

**review and offer referral from primary care if appropriate**

1.5.1.1 In most instances, if there have been two interventions provided (any combination of psychological intervention, medication, or bibliotherapy) and the person still has significant symptoms, then referral to specialist mental health services should be offered. D

1.6 **Step 5 for people with panic disorder:**

**care in specialist mental health services**

1.6.1.1 Specialist mental health services should conduct a thorough, holistic reassessment of the individual, their environment and social circumstances. This reassessment should include evaluation of:

- previous treatments, including effectiveness and concordance
- any substance use, including nicotine, alcohol, caffeine and recreational drugs
- comorbidities
- day-to-day functioning
- social networks
- continuing chronic stressors
- the role of agoraphobic and other avoidant symptoms.
A comprehensive risk assessment should be undertaken and an appropriate risk management plan developed. D

1.6.1.2 To undertake these evaluations, and to develop and share a full formulation, more than one session may be required and should be available. D

1.6.1.3 Care and management should be based on the individual’s circumstances and shared decisions made. Options include: D

- treatment of co-morbid conditions
- CBT with an experienced therapist if not offered already, including home-based CBT if attendance at clinic is difficult
- structured problem solving
- full exploration of pharmaco-therapy
- day support to relieve carers and family members
- referral for advice, assessment or management to tertiary centres.

1.6.1.4 There should be accurate and effective communication between all healthcare professionals involved in the care of any person with panic disorder, and particularly between primary care clinicians (GP and teams) and secondary care clinicians (community mental health teams) if there are existing physical health conditions that also require active management. D
Generalised anxiety disorder – steps 2–5

1.7 Step 2 for people with generalised anxiety disorder: offer treatment in primary care

The recommended treatment options have an evidence base: psychological therapy, medication and self-help have all been shown to be effective. The choice of treatment will be a consequence of the assessment process and shared decision-making.

There may be instances when the most effective intervention is not available (for example, cognitive behavioural therapy [CBT]) or is not the treatment option chosen by the patient. In these cases, the healthcare professional will need to consider, after discussion with the patient, whether it is acceptable to offer one of the other recommended treatments. If the preferred treatment option is currently unavailable, the healthcare professional will also have to consider whether it is likely to become available within a useful timeframe.

1.7.1 General

1.7.1.1 If immediate management of generalised anxiety disorder is necessary, any or all of the following should be considered:

- support and information D
- problem solving C
- benzodiazepines A
- sedating antihistamines A
- self-help. D

1.7.1.2 Benzodiazepines should not usually be used beyond 2–4 weeks. B

1.7.1.3 In the longer-term care of individuals with generalised anxiety disorder, any of the following types of intervention should be offered and the preference of the person with generalised anxiety disorder should be taken into account. The interventions which
have evidence for the longest duration of effect, in descending order, are:

- psychological therapy (see Section 1.7.2) A
- pharmacological therapy (antidepressant medication) (see Section 1.7.3) A
- self-help (see Section 1.7.4). A

1.7.1.4 The treatment option of choice should be available promptly. D

1.7.1.5 There are positive advantages of services based in primary care (for example, lower rates of people who do not attend) and these services are often preferred by patients. D

1.7.2 Psychological interventions

1.7.2.1 CBT should be used. A

1.7.2.2 CBT should be delivered only by suitably trained and supervised people who can demonstrate that they adhere closely to empirically grounded treatment protocols. A

1.7.2.3 CBT in the optimal range of duration (16–20 hours in total) should be offered. A

1.7.2.4 For most people, CBT should take the form of weekly sessions of 1–2 hours and be complete within a maximum of 4 months from commencement. B

1.7.2.5 Briefer CBT should be supplemented with appropriate focused information and tasks. A

1.7.2.6 Where briefer CBT is used, it should be around 8–10 hours and be designed to integrate with structured self-help materials. D
1.7.3 Pharmacological interventions – antidepressant medication

Antidepressants should be the only pharmacological intervention used in the longer-term management of generalised anxiety disorder. There is an evidence base for the effectiveness of the SSRIs. Paroxetine has a licence for the treatment of generalised anxiety disorder.

1.7.3.1 The following must be taken into account when deciding which medication to offer: D

- the age of the patient
- previous treatment response
- risks
  - the likelihood of accidental overdose by the person being treated and by other family members if appropriate
  - the likelihood of deliberate self-harm, by overdose or otherwise
- tolerability
- the preference of the person being treated
- cost, where equal effectiveness is demonstrated.

1.7.3.2 All patients who are prescribed antidepressants should be informed, at the time that treatment is initiated, of potential side effects (including transient increase in anxiety at the start of treatment) and of the risk of discontinuation/withdrawal symptoms if the treatment is stopped abruptly or in some instances if a dose is missed or, occasionally, on reducing the dose of the drug. C

1.7.3.3 Patients started on antidepressants should be informed about the delay in onset of effect, the time course of treatment and the need to take medication as prescribed, and possible discontinuation/withdrawal symptoms. Written information appropriate to the patient’s needs should be made available. D
1.7.3.4 Unless otherwise indicated, an SSRI should be offered. B

1.7.3.5 If one SSRI is not suitable or there is no improvement after a 12-week course, and if a further medication is appropriate, another SSRI should be offered. D

1.7.3.6 When prescribing an antidepressant, the healthcare professional should consider the following.

- Side effects on the initiation of antidepressants may be minimised by starting at a low dose and increasing the dose slowly until a satisfactory therapeutic response is achieved. D

- In some instances, doses at the upper end of the indicated dose range may be necessary and should be offered if needed. B

- Long-term treatment may be necessary for some people and should be offered if needed. B

- If the patient is showing improvement on treatment with an antidepressant, the drug should be continued for at least 6 months after the optimal dose is reached, after which the dose can be tapered. D

1.7.3.7 If there is no improvement after a 12-week course, another SSRI (if another medication is appropriate) or another form of therapy (see 1.7.1.3) should be offered. D

1.7.3.8 Patients should be advised to take their medication as prescribed. This may be particularly important with short half-life medication to avoid discontinuation/withdrawal symptoms. C

1.7.3.9 Stopping antidepressants abruptly can cause discontinuation/withdrawal symptoms. To minimise the risk of discontinuation/withdrawal symptoms when stopping
antidepressants, the dose should be reduced gradually over an extended period of time. C

1.7.3.10 All patients prescribed antidepressants should be informed that, although the drugs are not associated with tolerance and craving, discontinuation/withdrawal symptoms may occur on stopping or missing doses or, occasionally, on reducing the dose of the drug. These symptoms are usually mild and self-limiting but occasionally can be severe, particularly if the drug is stopped abruptly. C

1.7.3.11 Healthcare professionals should inform patients that the most commonly experienced discontinuation/withdrawal symptoms are dizziness, numbness and tingling, gastrointestinal disturbances (particularly nausea and vomiting), headache, sweating, anxiety and sleep disturbances. D

1.7.3.12 Healthcare professionals should inform patients that they should seek advice from their medical practitioner if they experience significant discontinuation/withdrawal symptoms. D

1.7.3.13 If discontinuation/withdrawal symptoms are mild, the practitioner should reassure the patient and monitor symptoms. If severe symptoms are experienced after discontinuing an antidepressant, the practitioner should consider reintroducing it (or prescribing another from the same class that has a longer half-life) and gradually reducing the dose while monitoring symptoms. D

1.7.4 Self-help

1.7.4.1 Bibliotherapy based on CBT principles should be offered. A

1.7.4.2 Information about support groups, where they are available, should be offered. (Support groups may provide face-to-face meetings, telephone conference support groups [which can be
based on CBT principles], or additional information on all aspects of anxiety disorders plus other sources of help.) D

1.7.4.3 Large-group CBT should be considered. C

1.7.4.4 The benefits of exercise as part of good general health should be discussed with all patients as appropriate. B

1.7.4.5 Current research suggests that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence is, however, an insufficient basis on which to recommend the general introduction of this technology into the NHS. NICE 2002

1.8 Step 3 for people with generalised anxiety disorder: review and offer alternative treatment if appropriate

1.8.1.1 If, following a course of treatment, the clinician and patient agree that there has been no improvement with one type of intervention, the patient should be reassessed and consideration given to trying one of the other types of intervention. D

1.9 Step 4 for people with generalised anxiety disorder: review and offer referral to specialist mental health services

1.9.1 Referral from primary care

1.9.1.1 In most instances, if there have been two interventions provided (any combination of psychological intervention, medication, or bibliotherapy) and the person still has significant symptoms, then referral to specialist mental health services should be offered. D
1.9.2 If venlafaxine is being considered

1.9.2.1 Venlafaxine treatment should only be initiated by specialist mental health medical practitioners including General Practitioners with a Special Interest in Mental Health. D

1.9.2.2 Venlafaxine treatment should only be managed under the supervision of specialist mental health medical practitioners including General Practitioners with a Special Interest in Mental Health. D

1.9.2.3 The dose of venlafaxine should be no higher than 75 mg per day. A

1.9.2.4 Before prescribing venlafaxine an initial ECG and blood pressure measurement should be undertaken. There should be regular monitoring of blood pressure, and monitoring of cardiac status as clinically appropriate. D

1.10 Step 5 for people with generalised anxiety disorder: care in specialist mental health services

1.10.1 Care in specialist mental health services

1.10.1.1 Specialist mental health services should conduct a thorough, holistic reassessment of the individual, their environment and social circumstances. This reassessment should include evaluation of:

- previous treatments, including effectiveness and concordance
- any substance use, including nicotine, alcohol, caffeine and recreational drugs
- comorbidities
- day-to-day functioning
- social networks
• continuing chronic stressors
• the role of agoraphobic and other avoidant symptoms.
A comprehensive risk assessment should be undertaken and an appropriate risk management plan developed. 

1.10.1.2 To undertake these evaluations, and to develop and share a full formulation, more than one session may be required and should be available. 

1.10.1.3 Care and management will be based on the individual’s circumstances and shared decisions arrived at. Options include: 
• treatment of co-morbid conditions
• CBT with an experienced therapist if not offered already, including home-based CBT if attendance at clinic is problematic
• structured problem solving
• full exploration of pharmaco-therapy
• day support to relieve carers and family members
• referral for advice, assessment or management to tertiary centres.

1.10.1.4 There should be accurate and effective communication between all healthcare professionals involved in the care of any person with generalised anxiety disorder and particularly between primary care clinicians (GP and teams) and secondary care clinicians (community mental health teams) if there are existing physical health conditions that also require active management.
1.11 Monitoring and follow-up (for individuals with panic disorder or generalised anxiety disorder)

1.11.1 Psychological interventions

1.11.1.1 There should be a process within each practice to assess the progress of a person undergoing CBT. The nature of that process should be determined on a case-by-case basis.

1.11.2 Pharmacological interventions

1.11.2.1 When a new medication is started, the efficacy and side-effects should be reviewed within 2 weeks of starting treatment and again at 4, 6 and 12 weeks. Follow the Summary of Product Characteristics (SPC) with respect to all other monitoring required.

1.11.2.2 At the end of 12 weeks, an assessment of the effectiveness of the treatment should be made, and a decision made as to whether to continue or consider an alternative intervention.

1.11.2.3 If medication is to be continued beyond 12 weeks, the individual should be reviewed at 8- to 12-week intervals, depending on clinical progress and individual circumstances.

1.11.3 Self-help

1.11.3.1 Individuals receiving self-help interventions should be offered contact with primary healthcare professionals, so that progress can be monitored and alternative interventions considered if appropriate. The frequency of such contact should be determined on a case-by-case basis, but is likely to be between every 4 and 8 weeks.
1.11.4 Outcome measures

1.11.4.1 Short, self-complete questionnaires (such as the panic subscale of the agoraphobic mobility inventory for individuals with panic disorder) should be used to monitor outcomes wherever possible. D

2 Notes on the scope of the guidance

All NICE guidelines are developed in accordance with a scope document that defines what the guideline will and will not cover. The scope of this guideline was established at the start of the development of this guideline, following a period of consultation; it is available from www.nice.org.uk/article.asp?a=30597

The guideline provides recommendations for all healthcare professionals in primary, secondary or community care who provide care for people who have panic disorder (with or without agoraphobia) or generalised anxiety disorder.

The scope of this guideline is the management of adults (aged 18 years or older) with a working diagnosis of panic disorder (with or without agoraphobia) or generalised anxiety disorder. The guideline does not cover the care of the following: children (people younger than 18 years); people with major depression; people with mixed anxiety and depression; people with bipolar depression; people with seasonal affective disorder (SAD); people with combat disorder; people with anxiety disorders associated with dementia; people with phobic disorders other than panic disorder with agoraphobia; people with organic brain disorders. The guideline also does not cover the care of people with post-traumatic stress disorder or obsessive–compulsive disorder, for which other NICE guidelines are being developed.
3 Implementation in the NHS

3.1 Resource implications

Local health communities should review their existing practice in the treatment and management of panic disorder and generalised anxiety disorder against this guideline. The review should consider the resources required to implement the recommendations set out in Section 1, the people and processes involved and the timeline over which full implementation is envisaged. It is in the interests of patients that the implementation timeline is as rapid as possible.

Relevant local clinical guidelines, care pathways and protocols should be reviewed in the light of this guidance and revised accordingly.

3.2 General

The implementation of this guideline will build on the National Service Frameworks for Mental Health in England and Wales and should form part of the service development plans for each local health community in England and Wales. The National Service Frameworks are available for England from www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/MentalHealth/fs/en, and for Wales from www.wales.nhs.uk/sites/home.cfm?orgid=438.

The National Institute for Mental Health in England (NIMHE), which is part of the NHS Modernisation Agency, is able to support the implementation of NICE guidelines through its regional development centres. More details can be found at www.nimhe.org.uk.

The introduction of the new general medical services (GMS) contract for primary care on 1 April 2004 provides a further opportunity to implement these guidelines. A draft quality and outcome framework (QOF) is provided as part of the Audit section (see Section 3.2 and Appendix D).
This guideline should be used in conjunction with the NICE guidance detailed in Section 6.

### 3.3 Audit

Suggested audit criteria are listed in Appendix D. These can be used as the basis for local clinical audit, at the discretion of those in practice.

As noted in 3.1, a draft quality and outcome framework is provided (see Appendix D). This new framework is not part of the standard GMS contract, but could be used by Personal Medical Services practices if they wish.

### 4 Key research recommendations

The following research recommendations have been identified for this NICE guideline, not as the most important research recommendations, but as those that are most representative of the full range of recommendations. The Guideline Development Group’s full set of research recommendations is detailed in the full guideline produced by the National Collaborating Centre for Primary Care (see Section 5).

- **4.1** Assessment of the cost effectiveness of all interventions in panic disorder and generalised anxiety disorder.

- **4.2** Comparison of the cost effectiveness of medication with psychological therapies and with combination therapy in panic disorder and generalised anxiety disorder.

- **4.3** Assessment of the cost effectiveness of various models of CBT, including consideration of:
  - the number of sessions
  - intervals between sessions
  - the length of sessions
  - substitution sessions CBT with increased homework.
4.4 Investigation of the duration of treatment with medication necessary in panic disorder and generalised anxiety disorder, to aid in making a decision that an adequate trial of therapy has been undertaken if medication is not proving effective.

4.5 Long-term follow-up studies for all therapies are also needed.

5 Other versions of this guideline

The National Institute for Clinical Excellence commissioned the development of this guidance from the National Collaborating Centre for Primary Care. The Centre established a Guideline Development Group, which reviewed the evidence and developed the recommendations. The members of the Guideline Development Group are listed in Appendix B. Information about the independent Guideline Review Panel is given in Appendix C.

The booklet *The Guideline Development Process – An Overview for Stakeholder, the Public and the NHS* has more information about the Institute’s guideline development process. It is available from the Institute’s website and copies can also be ordered by telephoning 0870 1555 455 and quoting reference number N0472).

5.1 Full guideline

The full guideline, *Clinical Guidelines for the Management of Panic Disorder and Generalised Anxiety Disorder*, is published by the National Collaborating Centre for Primary Care; it is available on its website (www.rcgp.org.uk/nccpc), the NICE website (www.nice.org.uk) and on the website of the National Electronic Library for Health (www.nelh.nhs.uk).

5.2 Quick reference guide

A quick reference guide for healthcare professionals is also available from the NICE website (www.nice.org.uk/CG022quickrefguide) or from the NHS Response Line (0870 1555 455; quote reference number N0763).
5.3 Information for the public

A version of this guideline for people with generalised anxiety disorder or panic disorder and for the public is available from the NICE website (www.nice.org.uk/CG022publicinfo) or from the NHS Response Line (0870 1555 455; quote reference number N0764 for an English version and N0765 for an English and Welsh version). This is a good starting point for explaining to patients the kind of care they can expect.

6 Related NICE guidance


Depression: the management of depression in primary and secondary care. NICE Clinical Guideline no. 23 (www.nice.org.uk/CG023).

NICE is in the process of developing the following guidance.


7 Review date

The process of reviewing the evidence is expected to begin 4 years after the date of issue of this guideline. Reviewing may begin earlier than 4 years if significant evidence that affects the guideline recommendations is identified sooner. The updated guideline will be available within 2 years of the start of the review process.
### Appendix A: Grading scheme

The grading scheme and hierarchy of evidence used in this guideline (see Table) is adapted from Eccles and Mason (2001).

<table>
<thead>
<tr>
<th>Recommendation grade</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Directly based on category I evidence</td>
</tr>
<tr>
<td>B</td>
<td>Directly based on:</td>
</tr>
<tr>
<td></td>
<td>- category II evidence, or</td>
</tr>
<tr>
<td></td>
<td>- extrapolated recommendation from category I evidence</td>
</tr>
<tr>
<td>C</td>
<td>Directly based on:</td>
</tr>
<tr>
<td></td>
<td>- category III evidence, or</td>
</tr>
<tr>
<td></td>
<td>- extrapolated recommendation from category I or II evidence</td>
</tr>
<tr>
<td>D</td>
<td>Directly based on:</td>
</tr>
<tr>
<td></td>
<td>- category IV evidence, or</td>
</tr>
<tr>
<td></td>
<td>- extrapolated recommendation from category I, II, or III evidence</td>
</tr>
</tbody>
</table>

**NICE 2002**

**Evidence category**

<table>
<thead>
<tr>
<th>Source</th>
<th>Evidence from:</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>- meta-analysis of randomised controlled trials, or</td>
</tr>
<tr>
<td></td>
<td>- at least one randomised controlled trial</td>
</tr>
<tr>
<td>II</td>
<td>Evidence from:</td>
</tr>
<tr>
<td></td>
<td>- at least one controlled study without randomisation, or</td>
</tr>
<tr>
<td></td>
<td>- at least one other type of quasi-experimental study</td>
</tr>
<tr>
<td>III</td>
<td>Evidence from non-experimental descriptive studies, such as</td>
</tr>
<tr>
<td></td>
<td>comparative studies, correlation studies and case–control studies</td>
</tr>
<tr>
<td>IV</td>
<td>Evidence from expert committee reports or opinions and/or</td>
</tr>
<tr>
<td></td>
<td>clinical experience of respected authorities</td>
</tr>
</tbody>
</table>

Appendix B: The Guideline Development Group

Dr Alan Cohen (Chair)
Director of Primary Care, Sainsbury Centre for Mental Health, London

Karen Beck (in attendance)
PA, Section of Public Health, School of Health and Related Research (ScHARR), University of Sheffield

Paul Dennis
Nurse Practitioner in Mental Health, Meadows Health Centre, Nottingham

Revd John Eatock
Senior Counsellor, Bolton, Salford & Trafford Mental Health Partnership & Lead Advisor, British Association for Counselling and Psychotherapy

Research Associate, ScHARR, University of Sheffield

Celia Feetam
Clinical Psychiatric Pharmacist, Aston University and Birmingham and Solihull Mental Health Trust

Dr John Hague
General Practitioner and Mental Health Lead, Ipswich Primary Care Trust

Dr Ian Hughes
Consultant Clinical Psychologist, Cardiff & Vale NHS Trust

Julie Kelly
Patient Representative, National Phobics Society

Dr Nick Kosky
Consultant Psychiatrist and Clinical Director, North Dorset Primary Care Trust

Geraldine Lear
Community Psychiatric Nurse, Nottinghamshire Healthcare NHS Trust
Aileen McIntosh
Deputy Director, Sheffield Evidence Based Guidelines Programme, Public Health, ScHARR, University of Sheffield

Lilian Owens
Patient Representative, No Panic

Julie Ratcliffe
Health Economist, Sheffield Health Economics Group, ScHARR, University of Sheffield

Professor Paul Salkovskis
Clinical Director of the Centre for Anxiety Disorders and Trauma, South London and Maudsley NHS Trust, and Professor of Clinical Psychology and Applied Science, Institute of Psychiatry, King’s College, London

Anthea Sutton (in attendance)
Information Officer, ScHARR, University of Sheffield

Nancy Turnbull (in attendance)
Chief Executive, National Collaborating Centre for Primary Care

Dr Allan Wailoo
Health Economist, Sheffield Health Economics Group, ScHARR, University of Sheffield (until January 2004)
Appendix C: The Guideline Review Panel

The Guideline Review Panel is an independent panel that oversees the development of the guideline and takes responsibility for monitoring its quality. The Panel includes experts on guideline methodology, health professionals and people with experience of the issues affecting patients and carers. The members of the Guideline Review Panel were as follows.

Professor Mike Drummond
Director, Centre for Health Economics, University of York

Dr Kevork Hopayian
General Practitioner, Leiston

Mr Barry Stables
Patient Representative

Dr Imogen Stephens
Joint Director of Public Health, Western Sussex Primary Care Trust

Dr Robert Walker
Clinical Director, West Cumbria Primary Care Trust
Appendix D: Technical detail on the criteria for audit

Audit criteria

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Exception</th>
<th>Definition of terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>The patient shares decision-making with the healthcare professionals</td>
<td>The patient with panic disorder or generalised anxiety disorder is unable to participate in an informed discussion with the clinician responsible for treatment at the time, and an advocate or carer is not available.</td>
<td></td>
</tr>
<tr>
<td>during the process of diagnosis and in all phases of care.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The patient and, when appropriate, his or her family and carer(s) are</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>offered appropriate information on the nature, course and treatment of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>panic disorder or generalised anxiety disorder, including information on</td>
<td></td>
<td></td>
</tr>
<tr>
<td>the use and likely side-effect profile of medication.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The patient and his or her family and carer(s) are informed of self-help</td>
<td>The patient with panic disorder or generalised anxiety disorder is unable to participate in self-help groups or support groups.</td>
<td></td>
</tr>
<tr>
<td>groups and support groups and are encouraged to participate in programmes.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients prescribed antidepressants are informed that, although the</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>drugs are not associated with tolerance and craving, discontinuation/</td>
<td></td>
<td></td>
</tr>
<tr>
<td>withdrawal symptoms may occur on stopping or missing doses or,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>occasionally, on reducing the dose of the drug. These symptoms are</td>
<td></td>
<td></td>
</tr>
<tr>
<td>usually mild and self-limiting but occasionally can be severe,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>particularly if the drug is stopped abruptly.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Necessary relevant information is elicited from</td>
<td>The patient with panic disorder or generalised anxiety disorder is unable to participate</td>
<td>Necessary relevant information can be defined</td>
</tr>
<tr>
<td></td>
<td>in an informed discussion with the clinician responsible for treatment at the time, and an advocate or carer is not available.</td>
<td></td>
</tr>
<tr>
<td>The treatment of choice is available promptly.</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Individuals with panic disorder are not prescribed benzodiazepines.</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>A patient with panic disorder is offered any of the following types of intervention, and the person's preference is taken into account: • psychological therapy • pharmacological therapy • self-help.</td>
<td>None, providing that there are no known drug sensitivities</td>
<td></td>
</tr>
<tr>
<td>Psychological therapy is CBT. Pharmacological therapy refers to an SSRI licensed for panic disorder; or if an SSRI is unsuitable or there is no improvement imipramine or clomipramine are considered. Self-help includes bibliotherapy based on CBT principles.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A patient with generalised anxiety disorder is not prescribed benzodiazepines for longer than 2–4 weeks.</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>A patient with longer-term generalised anxiety disorder is offered any of the following types of intervention, and the person's preference is taken into account • psychological therapy • pharmacological therapy • self-help.</td>
<td>as above</td>
<td></td>
</tr>
<tr>
<td>Psychological therapy is CBT. Pharmacological therapy is an SSRI. Self-help includes bibliotherapy based on CBT principles.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A patient is reassessed if one type of intervention does not work, and consideration is given to trying one of the other types of intervention.</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>A patient who still has significant symptoms after two interventions is offered referral to specialist</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Two interventions can be defined as any combination of psychological intervention,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mental health services.</td>
<td>medication or bibliotherapy.</td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>-------------------------------</td>
<td></td>
</tr>
<tr>
<td>A thorough, holistic re-assessment of the individual, his or her environment and social circumstances is conducted by specialist mental health services.</td>
<td>None, unless the patient refused referral</td>
<td></td>
</tr>
<tr>
<td>Outcomes are monitored using short, self-complete questionnaires.</td>
<td>The individual with panic disorder or generalised anxiety disorder is unable to participate in a discussion with the clinician responsible for treatment</td>
<td>A short self-complete questionnaire such as the panic subscale of the agoraphobic mobility inventory for individuals with panic disorder.</td>
</tr>
</tbody>
</table>
Quality and outcome framework

The changes to the contractual arrangements for primary care services, and particularly for general practitioners, have provided an opportunity to consider different ways of auditing the care that is provided through implementing these guidelines.

The new contractual arrangements provide a system for practices to be financially rewarded for delivering specific clinical outcomes in a number of different clinical domains. Although these clinical domains and the financial rewards are carefully described for GMS (general medical services) practices, there exists the flexibility to develop new and innovative clinical domains for PMS (personal medical services) practices.

The Guideline Development Group has therefore produced such a draft framework. The structure of this section mirrors the structure of a standard quality and outcome domain, but does not allocate any points, because this will be up to the discretion of the commissioning Primary Care Trust (PCT), and then by negotiation with the personal medical services (PMS) practices.

It should be stressed that PCTs, and PMS practices, may wish to amend and alter this draft framework to make it more appropriate for local needs.
Details of the rationale, indicators and proposed methods of data collection and monitoring

**Anxiety – rationale for inclusion of indicator set**

Anxiety is a common and debilitating condition that affects large numbers of people. Effective treatments are available. Anxiety frequently co-exists with other conditions, both physical and mental, and influences the resolution of these other conditions. Effective treatment for anxiety disorders will also have a beneficial impact on these other co-existing conditions.

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points*</th>
<th>Max threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A1a. The practice can produce a register of people with generalised anxiety disorder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A1b. The practice can produce a register of people with panic disorder</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Treatment options</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A2a. The percentage of people with generalised anxiety disorder on the register offered CBT</td>
<td>No score</td>
<td></td>
</tr>
<tr>
<td>A2b. The percentage of people with generalised anxiety disorder on the register offered medication</td>
<td>No score</td>
<td></td>
</tr>
<tr>
<td>A2c. The percentage of people with generalised anxiety disorder on the register offered bibliotherapy</td>
<td>No score</td>
<td></td>
</tr>
<tr>
<td>A2 Total: the sum of the above</td>
<td>25–90%</td>
<td></td>
</tr>
<tr>
<td>A3a. The percentage of people with panic disorder on the register offered CBT</td>
<td>No score</td>
<td></td>
</tr>
<tr>
<td>A3b. The percentage of people with panic disorder on the register offered medication <em>(a licensed SSRI, imipramine or clomipramine)</em></td>
<td>No score</td>
<td></td>
</tr>
<tr>
<td>A3c. The percentage of people with panic disorder on the register offered bibliotherapy</td>
<td>No score</td>
<td></td>
</tr>
<tr>
<td>A3 Total: the sum of the above</td>
<td>25–90%</td>
<td></td>
</tr>
<tr>
<td><strong>Referral to secondary care</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A4. The percentage of people on both registers who have been referred to secondary care services who have received two interventions in the last 12 months</td>
<td>25–70%</td>
<td></td>
</tr>
</tbody>
</table>

* To be agreed locally
Anxiety indicator 1
The practice can produce a register of either people with generalised anxiety disorder or panic disorder

Anxiety indicators 1a and 1b – rationale
To call and recall patients effectively in any disease category, and to be able to report on indicators, practices must be able to identify patients within the practice population who have either generalised anxiety disorder or panic disorder. Neither this quality and outcome framework nor the NICE guideline of which it is a part applies to people with mixed anxiety and depression, for which reference to the NICE depression guidelines should be made. This framework also does not apply to people who have a single panic attack, because they have not yet developed panic disorder.

Anxiety indicators 1a and 1b – preferred coding
Practices should record those with a current history of:

Generalised Anxiety Disorder Eu[X]41.1

Panic Disorder Eu[X]41.0.

Anxiety indicators 1a and 1b – reporting and validation
The practice reports the number of patients on both registers (for generalised anxiety disorder and panic disorder), and the number as a proportion of the total list size.

PCTs may compare the expected prevalence with the reported prevalence.

Anxiety indicators 2a, 2b, 2c and 2 Total
The number of patients with generalised anxiety disorder receiving either CBT, an approved medication, or self-help
**Anxiety indicators 2a, 2b, 2c and 2 Total – rationale**

This guideline provides the evidence for supporting shared decision-making in selecting treatments that are effective. These three indicators allow patient choice within the parameters of what is known to be effective. The sum of the total should account for all those on the generalised anxiety disorder register, to ensure that only effective interventions are offered.

**Anxiety indicators 2a, 2b, 2c and 2 Total – preferred coding**

Practices should record which medication, if any, is being prescribed.

Practices should record whether patients have been referred for CBT.

Practices should record whether patients have been referred for bibliotherapy.

**Anxiety indicators 2a, 2b, 2c and 2 Total – reporting and validation**

Practices should record the total percentage of patients on the generalised anxiety disorder register receiving an intervention.

PCTs should be able to scrutinise the computer print-out.

---

**Anxiety indicators 3a, 3b, 3c and 3 Total**

The number of patients with panic disorder receiving either CBT, an approved medication, or self-help

**Anxiety indicators 3a, 3b, 3c and 3 Total – rationale**

This guideline provides the evidence for supporting shared decision-making in selecting treatments that are effective. These three indicators allow patient choice within the parameters of what is known to be effective. The sum of the total should account for all those on the panic disorder register, to ensure that only effective interventions are offered.

**Anxiety indicators 3a, 3b, 3c and 3 Total – preferred coding**

Practices should record which medication, if any, is being prescribed.
Practices should record whether patients have been referred for CBT.

Practices should record whether patients have been referred for bibliotherapy.

**Anxiety indicators 3a, 3b, 3c and 3 Total – reporting and validation**

Practices should record the total percentage of patients on the panic disorder register receiving an intervention.

PCTs should be able to scrutinise the computer print-out.

### Anxiety indicator 4

The number of patients referred to specialist mental health services who have had two effective interventions, but failed to improve.

### Anxiety indicator 4 – rationale

The majority of patients with generalised anxiety disorder or panic disorder can and should be cared for in primary care. It is appropriate to consider referral to specialist mental health services if two effective interventions have failed to produce an improvement for the patient. There will always be other reasons why referral may be necessary, which allows a slightly lower target than for the other indicators.

### Anxiety indicator 4 – preferred coding

The practice should record which two interventions have been provided to patients who are referred.

### Anxiety indicator 4 – reporting and verification

Practices should be able to produce a list of patients referred to specialist services for the management of generalised anxiety disorder or panic disorder, and for each patient, the number of effective interventions that patients had received.
PCTs should be able to scrutinise the list produced by the practice.
Appendix E: The algorithms

Management of panic disorder in primary care: Steps 2–4

Management of generalised anxiety disorder in primary care: Steps 2–4
Management of panic disorder in primary care: Steps 2–4

Step 2: Offer treatment in primary care

**Psychological therapy**
- CBT should be used.
  - It should be delivered by trained and supervised people closely adhering to empirically grounded treatment protocols.
  - For most people, CBT should be in weekly sessions of 1–2 hours and be completed within a month.
  - The optimal range is 9–14 hours.
- If offering brief CBT, it should be about 7 hours, should be designed to integrate with structured self-help materials, and should be supplemented with appropriate focused information.
- Sometimes, more intensive CBT over a very short period might be appropriate.

**Pharmacological therapy**

*Before prescribing, consider:
- Side effects
- Previous treatment response
- Nausea when using anticholinergics or antidepressants
- Tolerance
- The patient’s preference
- Cost, where available efficiency

When prescribing:
- Offer an SSRI licensed for panic disorder, unless otherwise indicated.
- If an SSRI is not suitable or there is no improvement after a 12-week course, and if further medication is appropriate, consider risperidone or olanzapine.
- Inform patients of the risk treatment is initiated about:
  - Potential side effects (including transient increase in anxiety at the start of treatment)
  - Possible discontinuation/withdrawal symptoms (see recommendations 5.3.8–5.3.11)
  - Delay in onset of effect
  - Time course of treatment
- Need to take medication as prescribed (this may be particularly important with short half-life medication in order to avoid discontinuation/withdrawal symptoms).
- Written information appropriate for the patient’s needs should be made available.
- Side effects on initiation may be minimized by starting at a low dose and slowly increasing the dose until a satisfactory therapeutic response is achieved.
- Long-term treatment and doses at the upper end of the indicated dose range may be necessary.

**Self-help**

- Offer CBT based on CBT principles.
- Offer information about support groups, where available.

**Comprehensive psychological intervention therapy** may be of value. It is not clear that the evidence is based on an insufficient basis on which to recommend it as part of good general health.

*See www.nice.org.uk/GN56*
Management of generalised anxiety disorder in primary care: Steps 2–4

### Psychological therapy
- CBT should be used:
  - It should be delivered by trained and supervised people, closely adhering to well-established treatment protocols.
  - For most people, CBT should be in weekly sessions of 45–60 minutes and be delivered over at least 12 weeks.
  - The optimal number of sessions is not clear, but extended treatment may be beneficial.
  - If offering further CBT, it should be designed to integrate with structured self-help materials.

### Pharmacological therapy
- Before prescribing:
  - Age
  - Previous treatment response
  - Risks of deliberate self-harm or accidental overdose
  - Reluctancy
  - Patient’s preference
  - Cost, where equal effectiveness

### Monitoring
- Measures progress according to process within the practice to determine the nature of the process on a case-by-case basis.
- Use short, self-complete questionnaires to monitor outcomes whenever possible.

### Ongoing management
- Use with appropriate monitoring for 4 months after optimal dose reached; then dose can be reduced if appropriate, monitored and reviewed.
  - When stopping, reduce the dose gradually over an extended period.

### Step 4: Review and offer referral to specialist mental health services (see Section 1.18)
- If appropriate and the person still has significant symptoms, if relaxation is being considered:
  - Valsartan treatment should only be initiated by specialist mental health medical practitioners including general practitioners with a special interest in mental health and managed under the supervision of specialists.
  - In patients with severe hypertension, Valsartan should be used with a beta-blocker.
  - Valsartan treatment should be no higher than 75 mg per day.

**Note:** See www.nice.org.uk/CG891

---

**NICE Guideline – Anxiety**

52